There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it? “Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s. The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest. “Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.

Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World

Last week, I was in a meeting with the...

Indian Pharma Market (IPM) Highlights – January 2025

Overall IPM Performance: Monthly Growth: IPM monthly growth reached 8.4% in...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Marketing

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Policies/Sales

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Strategy

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Nutraceuticals: Health, Hope Or Hype?

Walk into almost any clinic today and you will...

When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies

“Lifestyle advice often asks patients to fight powerful evolutionary...

The Antifungal Blind Spot: India’s Quiet Clinical Crisis

A market analysis and clinical commentary on the growing...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Torrent Pharma–JB Chemicals Acquisition Report

Summary Torrent Pharmaceuticals (TRP) has signed definitive agreements...

Time for Pharma to Re-think its Way of Working

https://www.youtube.com/watch?v=BOO_CNxEzwQ Too many Medical Reps are chasing too few doctors,...

How a Delhi Dementia Daycare Is Reimagining Care for India’s Forgotten Millions

By MedicinMan Editorial Desk When Memory Fades, Humanity Must Not In...

Track and Trace: Indian Pharma – Current and Future Applicability

Pharmaceutical companies must contend with challenges from supply chain lapses (theft, diversion, S.O.P. deviations, product recalls, reverse logistics etc.) counterfeiting and stringent regulations. These challenges get compounded when dealing across the states and country business operations, besides that not only impact tangible profits but also the intangible brand credibility. In this context, there is also a credible increase in public awareness about the genuineness of medicine (in particular medicine that require cold chain) and their predictability of clinical outcomes. Providing visibility and full traceability becomes a paramount importance to both the Industry and the Govt. – A fool proof solution not only brings transparency in the system, but can also be a key differentiator, and undoubtedly can create immense opportunities for a competitive advantage.